Imricor Medical SystemsASX:IMR +4.48%47 PB Ratio is 34.54 as of Jun. 27, 2026, which is 426% above its 10-year median of 6.57. GuruFocus rates ASX:IMR with a GF Score™ of 47/100 and a GF Value™ of A$0.10 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Imricor Medical Systems ranks worse than 98.1% on this metric.
The historical rank and industry rank for Imricor Medical Systems's PB Ratio or its related term are showing as below:
ASX:IMR'
s PB Ratio Range Over the Past 10 Years
Min: 0.53 Med: 6.57 Max: 40.19
Current: 34.54
During the past 8 years, Imricor Medical Systems's highest PB Ratio was 40.19. The lowest was 0.53. And the median was 6.57.
ASX:IMR's PB Ratio is ranked worse than 98.1% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs ASX:IMR: 34.54
During the past 3 years, the average Book Value Per Share Growth Rate was -8.70% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Imricor Medical Systems was 2.70% per year. The lowest was -12.80% per year. And the median was -8.70% per year.
Back to Basics: PB Ratio
Imricor Medical Systems (ASX:IMR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Imricor Medical Systems's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imricor Medical Systems PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Imricor Medical Systems's PB Ratio distribution charts can be found below:
* The bar in red indicates where Imricor Medical Systems's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Imricor Medical Systems (ASX:IMR) has a PB Ratio of 34.54 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Imricor Medical Systems and its competitors. This is 426% above median its historical median of 6.57. Over the past decade, Imricor Medical Systems' PB Ratio has ranged from 0.53 to 40.19. According to the industry distribution chart, Imricor Medical Systems ranks #773 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 98.1%.
Is Imricor Medical Systems' PB Ratio too high?
Imricor Medical Systems' current PB Ratio of 34.54 is 426% above median its 10-year median of 6.57. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 40.19. The Medical Devices & Instruments industry median PB Ratio is 2.02. Imricor Medical Systems' value of 34.54 is 1609.9% above this industry median. Based on the distribution chart, Imricor Medical Systems ranks #773 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Imricor Medical Systems has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Imricor Medical Systems' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Imricor Medical Systems ranks #773 out of 788 companies for PB Ratio. This places Imricor Medical Systems in the lower half of its industry. The industry median PB Ratio is 2.02. Imricor Medical Systems' value of 34.54 is 1609.9% above this benchmark. Historically, Imricor Medical Systems' own PB Ratio has ranged from 0.53 to 40.19 over the past decade. While the company's 10-year median is 6.57 vs. the industry median of 2.02, Imricor Medical Systems has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Imricor Medical Systems's current PB Ratio of 34.54 is 1609.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Imricor Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imricor Medical Systems's current PB Ratio is 34.54, which is 426% above median its own 10-year median of 6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imricor Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Imricor Medical Systems (ASX:IMR) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.10, compared to a current price of A$1.87 — trading 1765% above its estimated fair value. The current PB Ratio is 34.54, which is 426% above median its 10-year median of 6.57 and 1609.9% above the Medical Devices & Instruments industry median of 2.02. Imricor Medical Systems' overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Imricor Medical Systems (ASX:IMR), the current PB Ratio is 34.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Imricor Medical Systems (ASX:IMR) Overvalued in 2026?
Based on GuruFocus' analysis, Imricor Medical Systems stock appears to be overvalued.
The current stock price of A$1.87 is trading 1765% above its estimated GF Value™ of A$0.10.
GuruFocus considers Imricor Medical Systems to be Significantly Overvalued.
Key valuation signals for ASX:IMR:
PB Ratio: 34.54 (426% above median its 10-year median of 6.57)
GF Value™: A$0.10 vs. price of A$1.87 (1765% above fair value)
Industry Position: 1609.9% above the Medical Devices & Instruments median (#773 of 788)
No single metric tells the full story. See the ASX:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Imricor Medical Systems Inc is a medical device company that develops MRI-guided technology to address issues with traditional X-ray ablation procedures. Its principal business activities are designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. The company's products include the Advantage-MR EP Recorder/Stimulator, Vision-MR Ablation Catheter, and Vision-MR Dispersive Electrode. Geographically, the company generates maximum revenue from Europe.
47GF Score
Get the complete analysis for ASX:IMR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IMR has been successfully added to your 
